"目录号: HY-14544
GPCR/G ProteinNeuronal Signaling-
Quetiapine(Ketipinor)是非典型的抗精神病化合物，可作用于精神分裂，狂躁和抑郁症。
相关产品
Clozapine N-oxide-Chlorpromazine hydrochloride-Pimavanserin-Brexpiprazole-Lorcaserin Hydrochloride-Scopolamine hydrobromide-Cariprazine hydrochloride-Harmine-Lu AE58054 Hydrochloride-TG6-10-1-Perphenazine-Aripiprazole-Ferulic acid sodium-Olanzapine-Sertindole-
生物活性
Description
Quetiapine(Ketipinor) is an atypical antipsychotic used in the treatment of schizophrenia, bipolar I mania, bipolar II depression, bipolar I depression.IC50 value: Target: 5-HT ReceptorQuetiapine is indicated for the treatment of schizophrenia as well as for the treatment of acute manic episodes associated with bipolar I disorder. The antipsychotic effect of quetiapine is thought by some to be mediated through antagonist activity at dopamine and serotonin receptors. Specifically the D1 and D2 dopamine, the alpha 1 adrenoreceptor and alpha 2 adrenoreceptor, and 5-HT1A and 5-HT2 serotonin receptor subtypes are antagonized. Quetiapine also has an antagonistic effect on the histamine H1 receptor.
Clinical Trial
Northwestern University
Bipolar Disorder
March 2016
Manhattan Psychiatric Center-Nathan Kline Institute for Psychiatric Research
Schizophrenia-Schizoaffective Disorder
December 2004
Phase 2-Phase 3
University of Cincinnati
Depression-Healthy
September 2008
Phase 4
New York State Psychiatric Institute-National Institute on Drug Abuse (NIDA)
Cannabis Dependence
August 2009
Phase 2
Bayside Health-AstraZeneca
Schizophrenia-Psychosis
October 2009
Phase 4
University of Regensburg-AstraZeneca
Schizophrenia
March 2008
Phase 4
Mayo Clinic
Dementia-Delirium
June 2014
Phase 1
Hospital de Clinicas de Porto Alegre
BIPOLAR DISORDER
March 2009
Phase 3
Massachusetts General Hospital
Bipolar Disorder-Mania
February 2005
Phase 4
Dartmouth-Hitchcock Medical Center-Augusta University-AstraZeneca
Schizophrenia-Schizoaffective Disorder-Psychotic Disorder-Substance Abuse-Alcohol Abuse
March 2004
Phase 4
VA Connecticut Healthcare System
Insomnia-Mental Health Disorder-Substance Use Disorder
July 2012
Phase 4
University of California, San Diego-University of South Florida
Anorexia Nervosa
July 2006
AstraZeneca
Postpartum Depressive Disorder
August 2007
Phase 2
Weill Medical College of Cornell University-AstraZeneca
Major Depression-Generalized Anxiety Disorder
September 2008
Phase 4
University of Cincinnati-AstraZeneca
Mood Disorders
June 2003
Phase 3
BC Women's Hospital & Health Centre
Postpartum Depression
April 2008
Centro de Investigación Biomédica en Red de Salud Mental
Bipolar Disorder
September 2010
Phase 3
University of Texas Southwestern Medical Center
Bipolar Disorder-Cocaine Dependence
November 2005
Phase 4
Douglas A Drossman, MD-AstraZeneca-University of North Carolina, Chapel Hill
Functional Bowel Disorders
February 2008
University of Calgary-Multiple Sclerosis Society of Canada
Multiple Sclerosis
December 2014
Phase 1-Phase 2
Indiana University School of Medicine-AstraZeneca-Indiana University
Major Depression
March 2009
Phase 4
Cambridge Health Alliance-AstraZeneca
Social Anxiety Disorder
March 2006
Phase 4
AstraZeneca
Major Depressive Disorder
April 2006
Phase 3
Dr. Reddy's Laboratories Limited
Healthy
June 2010
Phase 1
Loyola University
Depression-Anxiety
July 2009
Phase 4
National Taiwan University Hospital-National Science Council, Taiwan
Schizophrenia
January 2007
Phase 4
East Tennessee State University-AstraZeneca
Fibromyalgia
January 2008
Phase 4
New York State Psychiatric Institute-National Institute on Drug Abuse (NIDA)
Cannabis Dependence
October 2012
Phase 2
AstraZeneca
Borderline Personality Disorder
June 2004
Phase 2
University of California, San Diego-Abbott
Bipolar Disorder
December 2006
Phase 4
University of Tennessee Graduate School of Medicine
Psychomotor Agitation
November 2013
Phase 4
McMaster University
Major Depressive Disorder-Insomnia-Hot Flashes
June 2007
Phase 4
Guangzhou Mental Hospital-First Affiliated Hospital of Jinan University-Second Affiliated Hospital of Guangzhou Medical University-Guangzhou mental Hospital Attached to Guangzhou Civil Affairs Bureau
Bipolar Disorder
December 2008
Phase 4
University Hospitals Cleveland Medical Center
Bipolar Disorder
January 2012
Phase 4
University of Erlangen-Nürnberg-AstraZeneca-University of Erlangen-Nürnberg Medical School
Schizophrenia
April 2007
Phase 4
AstraZeneca
Schizophrenia
April 2009
Phase 3
Subhajit Chakravorty-Corporal Michael J. Crescenz VA Medical Center
Alcoholism-Sleep Initiation and Maintenance Disorders
August 2007
Phase 3
The University of Texas Health Science Center at San Antonio-AstraZeneca
Bipolar Disorder
April 2007
Phase 4
AstraZeneca
Bipolar Disorder
July 2005
Phase 4
AstraZeneca
Schizophrenia
November 2008
Phase 4
University Hospital Muenster-AstraZeneca
Specific Phobia
April 2009
Phase 2
Dartmouth-Hitchcock Medical Center
Alcohol Dependence
September 2010
Phase 2
Ruhr University of Bochum
Psychotic Depression
September 2008
Phase 3
RWTH Aachen University
Depression-Bipolar Disorder
June 2015
University of Medicine and Dentistry of New Jersey-AstraZeneca-Rutgers, The State University of New Jersey
Borderline Personality Disorder
May 2005
Phase 3
AstraZeneca
Major Depressive Disorder
December 2005
Phase 3
Taichung Veterans General Hospital
Schizophrenia-Bipolar
August 2009
Phase 4
National Institute on Alcohol Abuse and Alcoholism (NIAAA)-VA Office of Research and Development-National Institute on Drug Abuse (NIDA)-AstraZeneca
Alcoholism-Alcohol Abuse
December 2007
Phase 2
University of Texas Southwestern Medical Center-Stanley Medical Research Institute-University of North Tex
